A Randomized, 30-week, Active-controlled, Open Label, 2- Treatment Arm, Parallel-group, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine With or Without Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)

Trial Profile

A Randomized, 30-week, Active-controlled, Open Label, 2- Treatment Arm, Parallel-group, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine With or Without Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Insulin-glargine/lixisenatide (Primary) ; Insulin glargine
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms LixiLan-L
  • Sponsors Sanofi
  • Most Recent Events

    • 13 Jun 2017 Results of a post-hoc analysis evaluating the association between iGlarLixi, GV, and patient's satisfaction with their treatment's ability to control their diabetes presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 13 Jun 2017 Results of a propensity score-matched analysis to Compare LixiLan-L and GetGoal Duo-2 trials presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 13 Jun 2017 Results of dose capping data from two phase III studies (LixiLan-L and LixiLan-O) presented at the 77th Annual Scientific Sessions of the American Diabetes Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top